Zevra Therapeutics
Adam Smith, PhD, MSBE has a diverse work experience in the pharmaceutical and medical research field. Adam has held several leadership positions, including Vice President of Business Development and Commercial Operations at Zevra Therapeutics, where they played a major role in drug development strategies and commercialization. Adam has also worked as Vice President of Scientific Affairs and Senior Director of Research at KemPharm, where they managed the drug candidate pipeline and played a key role in multiple approved NDAs and INDs. Adam has also worked as a Scientific Consultant at the Florida Spine Institute, Cell Science Systems, and Life Science Solutions, LLC. Adam has a strong academic background with a Postdoctoral Fellowship in Neurosurgery and Brain Repair, and a Graduate Research Assistantship in Molecular Pharmacology and Physiology, both at the University of South Florida. Adam has published numerous peer-reviewed manuscripts and has expertise in drug development and solid-state chemistry.
Adam Smith holds a PhD in Pharmacology and Neuroscience from the University of South Florida - College of Medicine, which they obtained between 2007 and 2012. In addition, they earned an MS in Medical Sciences from the same university from 2009 to 2010, and an MS in Biomedical Engineering from the University of South Florida - College of Engineering from 2007 to 2008. Adam Smith's undergraduate degree is a BS in Biomedical Sciences from the University of South Florida - College of Arts & Sciences, which they completed from 2005 to 2007.
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.